Published by Josh White on 21st February 2022
(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.
URL: http://www.digitallook.com/dl/news/story/32476628/...